![Logo der Firma 4SC AG](http://cdn.lifepr.de/f/8f6a8c1b7b79e3dd/logos/7524/500_500.gif)
4SC presents final results from Phase I AEGIS trial as well as rationale for daily dosing scheme of 4SC-205 cancer compound at ASCO
Daily dosage of oral, anti-mitotic Eg5 inhibitor shows good safety and tolerability. Specifically, no peripheral neuropa…